Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: Evidence for an age-statin interaction

Journal of the American Geriatrics Society

Volumn 54, Issue 3, 2006, Pages 421-430

  Micale Foody, Joanne ^a,b,c,d,e   Rathore, Saif S ^a   Galusha, Deron ^b   Masoudi, Frederick A ^d,f,g   Havranek, Edward P ^d,f,g   Radford, Martha J ^a,b   Krumholz, Harlan M ^a,b,d,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d West Haven Veterans Affairs Medical Center ^*  (United States)

^e QUALIDIGM   (United States)

^f DENVER HEALTH MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Elderly; Lipids; Myocardial infarction; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; AGED; AGING; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HAZARD ASSESSMENT; HOSPITAL; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICARE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHYSICIAN; PRESCRIPTION; TIME SERIES ANALYSIS;

AGE FACTORS; AGED, 80 AND OVER; CHOLESTEROL, LDL; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PRAVASTATIN; PRESCRIPTIONS, DRUG; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33644662738     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.00635.x     Document Type: Article

References (42)

1. Ko DT Mamdani M Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients The treatment-risk paradox JAMA 2004 291 1864 1870
2. Pitt B Mancini G Ellis S. Pravastatin limitation of atherosclerosis in the coronary arteris (PLAC I) Reduction in atherosclerosis progression and clinical events J Am Coll Cardiol 1995 26 1133 1136
3. Pfeffer MA Keech A Sacks FM et al Safety and tolerability of pravastatin in long-term clinical trials. Prospective Pravastatin Pooling (PPP) Project Circulation 2002 105 2341 2346
4. Sacks FM Pfeffer MA Moye LA et al The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators N Engl J Med 1996 335 1001 1009
5. Collins R Armitage J Parish S et al MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes A randomised placebo-controlled trial Lancet 2003 361 2005 2016
6. Schwartz G Olsson A Ezekowitz M et al Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes The MIRACL study: A randomized controlled trial JAMA 2001 285 1711 1718
7. Aronow W Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >orCombining double low line125 mg/dl treated with statins versus no lipid-lowering drug Am J Cardiol 2002 89 67 69
8. Cannon C Braunwald E McCabe C et al Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 2004 350 1495 1504
9. Foody JM Wang Y Kiefe CI et al Long-term prognostic importance of total cholesterol in elderly survivors of an acute myocardial infarction The Cooperative Cardiovascular Pilot Project J Am Geriatr Soc 2003 51 930 936
10. Krumholz H Gross C Peterson E et al Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study Am Heart J 2003 146 839 847
11. Grundy SM Cleeman JI Merz CNB et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004 110 227 239
12. Pasternak RC Smith SC Jr. Bairey-Merz CN et al ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 2002 40 567 572
13. Krumholz H Vaccarino V Mendes de Leon C et al Cholesterol and coronary heart disease mortality in elderly patients JAMA 1996 275 110 111
14. Krumholz HM Seeman TE Merrill SS et al Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years JAMA 1994 272 1335 1340
15. Kronmal RA Manolio TA Ettinger WH et al The relationship of lipid levels to five year mortality in a healthy elderly cohort The Cardiovascular Health Study Circulation 1996 94 I 94
16. Kronmal RA Cain KC Ye Z et al Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data Arch Intern Med 1993 153 1065 1073
17. Welch HG Albersen PC Nease RF et al Estimating treatment benefits for the elderly The effect of competing risks Ann Intern Med 1996 124 577 584
18. Corti MC Guralnik JM Salive ME et al Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons Ann Intern Med 1997 126 753 760
19. Lakatta EG Levy D. Arterial and cardiac aging Major shareholders in cardiovascular disease enterprises: Part I. Aging arteries: A 'set up' for vascular disease Circulation 2003 107 139 146
20. Tinetti ME Fried T. The end of the disease era Am J Med 2004 116 179 185
21. Jencks S Wilensky G. The Health Care Quality Improvement Initiative A new approach to quality assurance in Medicare JAMA 1992 268 900 903
22. Jencks S Cuerdon T Burwen D et al Quality of medical care delivered to Medicare beneficiaries A profile at state and national levels JAMA 2000 284 1670 1676
23. Lauer MS Blackstone EH Young JB et al Cause of death in clinical research: Time for a reassessment? J Am Coll Cardidol 1999 34 618 620
24. Radford MJ Foody JM. How do observational studies expand the evidence base for therapy? JAMA 2001 286 1228 1230
25. Rubin DB Thomas N. Matching using estimated propensity scores Relating theory to practice Biometrics 1996 52 249 264
26. Krumholz H Chen J Wang Y et al Comparing AMI mortality among hospitals in patients 65 years of age and older Evaluating methods of risk adjustment Circulation 1999 99 2986 2992
27. Matthews JNS Altman DG. Statistics note Interaction 3 How to examine heterogeneity BMJ 1996 313 862 870
28. Bellosta S Paoletti R Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions Circulation 2004 109 Suppl. 1 III50 III57
29. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk Cardiovasc Drugs Ther 2003 17 265 285
30. Guralnik J Simonsick E Ferrucci L et al A short physical performance battery assessing lower extremity function Association with self-reported disability and prediction of mortality and nursing home admission J Gerontol 1994 49 M85 M94
31. Tinetti ME Bogardus ST Jr. Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions N Engl J Med 2004 351 2870 2874
32. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344 1383 1389
33. Sacks FM Pfeffer MA Moye LA et al The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 1996 335 1001 1009
34. Shepherd J Blauw G Murphy M et al Pravastatin in elderly individuals at risk of vascular disease (PROSPER) A randomised controlled trial Lancet 2002 360 1623 1630
35. de Lemos JA Blazing MA Wiviott SD et al Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes Phase Z of the A to Z trial JAMA 2004 292 1307 1316
36. Britton A McKee M Black N et al Threats to applicability of randomised trials Exclusions and selective participation J Health Serv Res Policy 1999 4 112 121
37. Greer A. The state of the art versus the state of the science Intl J Technol Assess 1988 4 5 26
38. Rothwell PM. Can overall results of clinical trials be applied to all patients Lancet 1995 345 1616 1619
39. Lee PY Alexander KP Hammill BG et al Representation of elderly persons and women in published randomized trials of acute coronary syndromes JAMA 2001 286 708 713
40. Denke MA Grundy SM. Hypercholesterolemia in elderly persons Resolving the treatment dilemma Ann Intern Med 1990 112 780 792
41. Krumholz H Hennen J Ridker P et al Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly J Am Coll Cardiol 1998 31 973 979
42. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group Lancet 1994 343 311 322